Security Snapshot

PTC THERAPEUTICS INC - NOTE 1.500% 9/1 Institutional Ownership

CUSIP: 69366JAD3

13F Institutional Holders and Ownership History from Q2 2022 to Q2 2026

Latest Period

Q2 2026

Institutions Reporting

8

Principal

$56,053,000

Price (% of par)

156.97%

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 3 signals
Principal change
-$179,431,000
Market value change
-$260,506,497
Number of holders
8
Issuer context Names, identifiers, and filing context for this profile. 1 identity field
SEC-reported market price (% of par)
156.97%
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • 69366JAD3 - PTC THERAPEUTICS INC - NOTE 1.500% 9/1 is tracked under CUSIP 69366JAD3.
  • 8 institutions reported positions in Q2 2026.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder count moved from 15 to 8 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $331,202,924 to $84,077,565.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 8 institutions filings for Q2 2026.

Open SEC evidence

Security key

69366JAD3

Latest holder period

Q2 2026

13F holders

8

13D/G owners

0

CIK / CUSIP context first

As of 30 Jun 2026, 8 institutional investors reported holding $56,053,000 in principal (par value) of PTC THERAPEUTICS INC - NOTE 1.500% 9/1.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
17
Latest
Q2 2026
Rows shown
1-17 of 17
Period Principal Value Change Price (% of par) (Median) Investors
2026 Q2 $56,053,000 $84,077,565 -$260,506,497 156.97% 8
2026 Q1 $233,296,000 $331,202,924 +$19,586,217 133.42% 15
2025 Q4 $232,857,000 $346,049,605 +$11,387,320 148.24% 14
2025 Q3 $278,232,000 $296,027,478 +$725,502 128.25% 15
2025 Q2 $275,383,000 $318,055,093 -$3,252,102 115.48% 15
2025 Q1 $276,612,000 $326,799,984 +$764,592 117.03% 14
2024 Q4 $264,421,591 $309,275,303 -$20,168,580 111.67% 13
2024 Q3 $259,449,591 $309,774,451 +$582,114 103.98% 12
2024 Q2 $259,449,591 $284,800,544 +$182,994 95.4% 12
2024 Q1 $274,717,308 $277,129,832 -$20,916,765,749 93.25% 14
2023 Q4 $287,509,503 $273,105,852 +$15,160,001 91.88% 14
2023 Q3 $278,652,272 $229,332,855 -$3,058,195 79.7% 20
2023 Q2 $287,637,000 $296,005,222 -$2,491,781 102.75% 19
2023 Q1 $279,704,527 $327,735,385 +$7,856,990 113.7% 17
2022 Q4 $287,400,000 $284,218,480 -$1,258,207 98.54% 10
2022 Q3 $287,600,000 $336,226,000 +$32,736,045 117.21% 11
2022 Q2 $262,509,000 $275,443,000 +$275,443,000 104.71% 10
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .